Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab [1]

Annals of Hematology

Volumn 84, Issue 8, 2005, Pages 545-547

  Vallet, Sophie ^a   Tempescul, A ^a   Tran, A ^a   Legrand Quillien, M C ^a   Narbonne, V ^a   Berthou, C ^a  

^a CHU MORVAN   (France)

Author keywords

Cytomegalovirus recurrence; Mantel cell lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; HUMAN; LETTER; MALE; MANTLE CELL LYMPHOMA; MENINGORADICULONEURITIS; NEURITIS; PRIORITY JOURNAL; VIRUS MENINGITIS; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, MANTLE-CELL; MALE; MENINGITIS, VIRAL; MIDDLE AGED; RADICULOPATHY;

EID: 22344448691     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1038-0     Document Type: Letter

References (11)

1. Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520-535
2. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A (2000) Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894-895
3. Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000 10.1056/ NEJM200109273451315
4. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, Imrit K, Preti RA (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486-1488
5. Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, Peigue-Lafeuille H, Blanche S, Fischer A, Casanova JL, Travade P, Tardieu M (2003) Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 36:e47-e49
6. Hernandez JA, Diloy R, Salat D, del Rio N, Martinez X, Castellvi JM (2003) Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 88:ECR22
7. Song KW, Mollee P, Patterson B, Brien W, Crump M (2002) Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 119:125-127
8. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N (2004) Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 83:58-60
9. Flohr T, Hess GR, Kreiter S, Meyer RG, Huber C, Derigs G (2000) Immune reconstitution after autologous CD34-positive selected peripheral blood stem cell transplantation combined with rituximab for refractory B-cell non-Hodgkin's lymphoma. Blood 96:709a (abstract)
10. Horwitz SM, Breslin S, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor T, Brown BW, Blume KG, Horning SJ (2000) Adjuvant rituximab after autologous peripheral blood stem cell transplant results in delayed immune reconstitution with increase in infectious complications. Blood 96:707a (abstract)
11. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833 1:CAS:528:DyaK1cXlsFCgu7c%3D